Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O
Department of Physiology, Kinki University School of Medicine, Osakasayama City, Osaka, Japan.
Blood Coagul Fibrinolysis. 2000 Oct;11(7):645-55. doi: 10.1097/00001721-200010000-00009.
Staphylokinase (SAK) expresses plasminogen activator (PA) activity by forming a complex with plasmin; this PA activity is inhibited by alpha2-antiplasmin (alpha2-AP) in plasma. However, SAK's activity is protected against inhibition by alpha2-AP in the presence of fibrin because the plasmin-SAK complex binds to fibrin. In the present study, the interaction between SAK and murine plasminogen was investigated in the plasma of alpha2-AP-deficient (alpha2-AP-/-) mice or plasminogen-deficient (Plg-/-) mice. Although the human plasmin-SAK complex was formed in equimolar mixtures of plasmin and SAK, the murine plasmin-SAK complex was not formed. Human plasminogen was activated by the human plasmin-SAK complex, although equimolar mixtures of murine plasmin and SAK did not activate murine plasminogen. These findings suggest that SAK does not react with murine plasmin. However, the murine plasminogen was activated by the human plasmin-SAK complex, although this activation was approximately 100-fold weaker than human plasminogen. Human and wild-type mouse plasminogens were not activated by the human plasmin-SAK complex in their plasma. In alpha2-AP-/- mouse plasma, murine plasminogen was activated by the human plasmin-SAK complex. Human or murine plasminogen, which had been added to Plg-/- mouse plasma, was not activated by the human plasmin-SAK complex. However, plasma clot lysis by the human plasmin-SAK complex was observed in both human and murine plasma. These findings indicate that: (1) murine plasmin does not react with SAK, (2) human plasmin-SAK complex activates murine plasminogen, (3) this activation is inhibited by murine alpha2-AP, but (4) this activation is not inhibited by murine alpha2-AP in the presence of fibrin.
葡萄球菌激酶(SAK)通过与纤溶酶形成复合物来表达纤溶酶原激活剂(PA)活性;这种PA活性在血浆中会被α2-抗纤溶酶(α2-AP)抑制。然而,在有纤维蛋白存在的情况下,SAK的活性可免受α2-AP的抑制,因为纤溶酶-SAK复合物会与纤维蛋白结合。在本研究中,在α2-AP缺陷(α2-AP-/-)小鼠或纤溶酶原缺陷(Plg-/-)小鼠的血浆中研究了SAK与小鼠纤溶酶原之间的相互作用。尽管人纤溶酶和SAK的等摩尔混合物中形成了人纤溶酶-SAK复合物,但未形成小鼠纤溶酶-SAK复合物。人纤溶酶-SAK复合物可激活人纤溶酶原,尽管小鼠纤溶酶和SAK的等摩尔混合物不能激活小鼠纤溶酶原。这些发现表明SAK不与小鼠纤溶酶反应。然而,人纤溶酶-SAK复合物可激活小鼠纤溶酶原,尽管这种激活作用比激活人纤溶酶原弱约100倍。人血浆和野生型小鼠血浆中的人纤溶酶-SAK复合物不会激活其中的人或小鼠纤溶酶原。在α2-AP-/-小鼠血浆中,人纤溶酶-SAK复合物可激活小鼠纤溶酶原。添加到Plg-/-小鼠血浆中的人或小鼠纤溶酶原不会被人纤溶酶-SAK复合物激活。然而,在人血浆和小鼠血浆中均观察到了人纤溶酶-SAK复合物引起的血浆凝块溶解。这些发现表明:(1)小鼠纤溶酶不与SAK反应;(2)人纤溶酶-SAK复合物可激活小鼠纤溶酶原;(3)这种激活作用会被小鼠α2-AP抑制,但(4)在有纤维蛋白存在的情况下,这种激活作用不会被小鼠α2-AP抑制。